Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0036572 (
seizures
)
80,221
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We report a 21-year-old male patient with
dentatorubral-pallidoluysian atrophy
(
DRPLA
) showing progressive myoclonus epilepsy (PME), who responded to levetiracetam (LEV) at an initial dose of 1,000 mg/day. The patient developed epilepsy at the age of 10 years, and also showed intellectual regression. Various antiepileptic drugs showed no effects on generalized tonic
seizures
, tonic-clonic
seizures
, and myoclonus. Addition of LEV (1,000 mg/day) led to the reduction of myoclonus and tonic-clonic
seizures
, and improved the EEG and sleep-wake rhythm. He had a better appetite and gain weight. It is suggested that LEV may improve quality of life in patients with
DRPLA
, in addition to reducing the frequency of epileptic
seizures
.
...
PMID:[Successful treatment of epilepsy and circadian rhythm disturbance with levetiracetam in a patient with dentatorubral-pallidoluysian atrophy (DRPLA)]. 2555 87
Dentatorubral-pallidoluysian atrophy (DRPLA) is hereditary spinocerebellar degeneration presenting various symptoms in association with expansion of the CAG repeat in
Atrophin-1
gene. The functional neuroimaging of DRPLA has been poorly investigated. The purpose of this study was to examine (18)F-fluorodeoxyglucose-positron emission tomography ((18)F-FDG-PET) findings of DRPLA. We retrospectively investigated the cases of 14 consecutive genetically confirmed DRPLA patients at our institute. Four juvenile-onset patients underwent (18)F-FDG-PET because of intractable
seizures
. Their (18)F-FDG-PET images, clinical profiles and MRI findings were evaluated. For quantitative comparison, 3 healthy volunteers also underwent (18)F-FDG-PET as controls. All four patients presented progressive myoclonus epilepsy without MRI abnormalities. Both the visual and quantitative assessments of their (18)F-FDG-PET findings demonstrated bistriatal hypometabolism in only the two preadolescent-onset patients with larger CAG repeat size, whereas the two other later-onset patients showed no hypometabolism in the striatum. Bistriatal glucose hypometabolism in preadolescent-onset DRPLA patients might reflect more severe degeneration. This finding could contribute to a better understanding of DRPLA.
...
PMID:Striatal glucose hypometabolism in preadolescent-onset dentatorubral-pallidoluysian atrophy. 2672 87
We administered perampanel (PER) to a bedridden 13-year-old male patient with
dentatorubral-pallidoluysian atrophy
(
DRPLA
). The
DRPLA
diagnosis was based on the presence of a CAG trinucleotide repeat in the
ATN1
gene. The patient experienced continuous myoclonic
seizures
and weekly generalized tonic-clonic
seizures
(GTCs). PER stopped the patient's myoclonic
seizures
and reduced the GTCs to fragmented clonic
seizures
. The patient recovered his intellectual abilities and began to walk again with assistance. We suggest that PER be considered as one of the key drugs used to treat patients with
DRPLA
.
...
PMID:Efficacy of perampanel for controlling seizures and improving neurological dysfunction in a patient with dentatorubral-pallidoluysian atrophy (DRPLA). 2885 97
<< Previous
1
2